New program aims to help heart patients hit cholesterol targets

NCT ID NCT07034690

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a targeted lipid optimization program—combining clinic visits and virtual sessions—helps high-risk heart disease patients in Abu Dhabi achieve better LDL cholesterol control. About 326 adults with atherosclerotic cardiovascular disease will be randomly assigned to the program or standard care. The goal is to see if more patients reach their personalized cholesterol targets, potentially reducing future heart events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Educational program and virtual sessions to optimize lipid management
What this could lead to
If successful, this program could provide a practical way to help more patients reach their cholesterol goals and lower their risk of heart attacks or strokes.
What could go wrong
This is a Phase 4 study testing an educational program, not a new drug. The results may not apply to other regions or healthcare systems, and patient adherence to the program could vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Abu Dhabi, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.